13.32
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt SRPT?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$14.07
Offen:
$12.815
24-Stunden-Volumen:
23.80M
Relative Volume:
3.40
Marktkapitalisierung:
$1.31B
Einnahmen:
$2.23B
Nettoeinkommen (Verlust:
$-248.39M
KGV:
-4.9517
EPS:
-2.69
Netto-Cashflow:
$-697.55M
1W Leistung:
-30.73%
1M Leistung:
-33.67%
6M Leistung:
-88.59%
1J Leistung:
-90.85%
Sarepta Therapeutics Inc Stock (SRPT) Company Profile
Firmenname
Sarepta Therapeutics Inc
Sektor
Branche
Telefon
617-274-4000
Adresse
215 FIRST STREET, CAMBRIDGE, MA
Vergleichen Sie SRPT mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
SRPT
Sarepta Therapeutics Inc
|
13.32 | 1.89B | 2.23B | -248.39M | -697.55M | -2.69 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
458.49 | 121.30B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
545.53 | 61.60B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
320.52 | 41.17B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
566.14 | 34.35B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
291.93 | 27.29B | 3.81B | -644.79M | -669.77M | -6.24 |
Sarepta Therapeutics Inc Stock (SRPT) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2025-07-18 | Herabstufung | Needham | Buy → Hold |
2025-06-20 | Herabstufung | William Blair | Outperform → Mkt Perform |
2025-06-18 | Herabstufung | TD Cowen | Buy → Hold |
2025-06-17 | Eingeleitet | Wolfe Research | Peer Perform |
2025-06-16 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
2025-06-16 | Herabstufung | BofA Securities | Buy → Neutral |
2025-06-16 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
2025-06-16 | Herabstufung | H.C. Wainwright | Neutral → Sell |
2025-06-16 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
2025-06-16 | Herabstufung | Piper Sandler | Overweight → Neutral |
2025-06-06 | Hochstufung | Scotiabank | Sector Perform → Sector Outperform |
2025-05-08 | Herabstufung | Evercore ISI | Outperform → In-line |
2025-04-11 | Eingeleitet | Wells Fargo | Overweight |
2025-04-02 | Hochstufung | H.C. Wainwright | Sell → Neutral |
2025-03-31 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
2025-02-11 | Eingeleitet | Deutsche Bank | Hold |
2024-11-27 | Bestätigt | Needham | Buy |
2024-11-25 | Eingeleitet | H.C. Wainwright | Sell |
2024-11-07 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
2024-10-21 | Eingeleitet | Jefferies | Buy |
2024-10-10 | Fortgesetzt | Raymond James | Outperform |
2024-07-29 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
2024-06-26 | Herabstufung | Citigroup | Buy → Neutral |
2024-05-31 | Eingeleitet | Piper Sandler | Overweight |
2024-05-28 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
2024-05-14 | Hochstufung | Oppenheimer | Perform → Outperform |
2024-01-31 | Eingeleitet | BMO Capital Markets | Outperform |
2023-12-13 | Fortgesetzt | Citigroup | Buy |
2023-12-12 | Eingeleitet | Deutsche Bank | Buy |
2023-11-21 | Eingeleitet | Wedbush | Outperform |
2023-10-31 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
2023-10-31 | Herabstufung | Oppenheimer | Outperform → Perform |
2023-06-23 | Herabstufung | Evercore ISI | Outperform → In-line |
2023-04-26 | Eingeleitet | SMBC Nikko | Outperform |
2023-04-04 | Eingeleitet | Citigroup | Buy |
2023-03-01 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
2022-12-22 | Bestätigt | BTIG Research | Buy |
2022-12-16 | Hochstufung | UBS | Neutral → Buy |
2022-04-04 | Fortgesetzt | Cantor Fitzgerald | Overweight |
2022-01-05 | Bestätigt | Needham | Buy |
2021-12-09 | Hochstufung | Oppenheimer | Perform → Outperform |
2021-11-05 | Hochstufung | JP Morgan | Neutral → Overweight |
2021-09-15 | Hochstufung | Guggenheim | Neutral → Buy |
2021-08-05 | Hochstufung | JP Morgan | Underweight → Neutral |
2021-06-15 | Eingeleitet | BTIG Research | Buy |
2021-04-26 | Fortgesetzt | Credit Suisse | Neutral |
2021-01-12 | Herabstufung | Citigroup | Buy → Neutral |
2021-01-11 | Herabstufung | UBS | Buy → Neutral |
2021-01-08 | Herabstufung | JP Morgan | Overweight → Underweight |
2021-01-08 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
2021-01-08 | Herabstufung | Raymond James | Outperform → Mkt Perform |
2020-11-11 | Eingeleitet | Berenberg | Hold |
2020-10-28 | Eingeleitet | UBS | Buy |
2020-08-25 | Eingeleitet | Raymond James | Outperform |
2020-08-20 | Herabstufung | Credit Suisse | Outperform → Neutral |
2020-03-31 | Eingeleitet | Mizuho | Buy |
2019-11-01 | Eingeleitet | Guggenheim | Buy |
2019-08-21 | Bestätigt | Needham | Buy |
2019-07-09 | Bestätigt | Morgan Stanley | Overweight |
2019-07-01 | Bestätigt | RBC Capital Mkts | Outperform |
2019-04-12 | Eingeleitet | Evercore ISI | Outperform |
2019-03-11 | Bestätigt | Credit Suisse | Outperform |
2018-10-12 | Eingeleitet | Bernstein | Outperform |
2018-10-01 | Eingeleitet | Cantor Fitzgerald | Overweight |
2018-09-26 | Bestätigt | RBC Capital Mkts | Outperform |
2018-09-14 | Fortgesetzt | BofA/Merrill | Buy |
2018-09-06 | Eingeleitet | Credit Suisse | Outperform |
2018-08-01 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
2018-06-21 | Bestätigt | Robert W. Baird | Outperform |
2018-06-20 | Bestätigt | Needham | Buy |
2018-06-19 | Bestätigt | H.C. Wainwright | Buy |
Alle ansehen
Sarepta Therapeutics Inc Aktie (SRPT) Neueste Nachrichten
Sarepta’s Elevidys Halted at Children’s Hospital Los Angeles - Bloomberg
Drugmaker Refuses F.D.A. Request to Pull Treatment Linked to Patient Deaths - The New York Times
Sarepta under pressure: FDA requests halt of Elevidys shipments - Yahoo Finance
Sarepta Worth $0 Amid ‘Unwinnable’ FDA Fight, HC Wainwright Says - Bloomberg
Sarepta Dives, Again, As Its 'Unprecedented Times' Continue - Investor's Business Daily
Sarepta Therapeutics laying off dozens in Ohio, won't comply with FDA request to halt therapy - The Columbus Dispatch
Sarepta Faces Regulatory Showdown As Analysts Cut Price Targets - Benzinga
The crisis over Sarepta’s Duchenne therapy is a mess. But the lesson is clear - statnews.com
Sarepta shares cut to $0 at H.C. Wainwright (SRPT:NASDAQ) - Seeking Alpha
Drugmaker Refuses FDA's Request to Pull Gene Therapy Tied to Patient Deaths - MedPage Today
Navigating the Crossroads of Innovation and Safety: Assessing Sarepta Therapeutics in the Gene Therapy Landscape - AInvest
Sarepta refuses to pull gene therapy despite FDA order - Yahoo Finance
Arrowhead hits the skids due to partnership with Sarepta - Seeking Alpha
Sarepta LGMD trials all hit by FDA hold amid newly surfaced safety concerns over gene therapy - Fierce Biotech
SRPT Down After Third Death in Muscular Dystrophy Gene Therapy Program - Yahoo Finance
Sarepta stands behind Elevidys after FDA requests gene therapy be pulled from market - Fierce Pharma
Sarepta Stock Is Falling. How Its Crisis Went From Bad to Worse. - Barron's
Sarepta Stock Keeps Sliding as Company Rejects FDA Call to Withdraw Drug - Investopedia
SRPT Investors Have Opportunity to Join Sarepta Therapeutics, Inc. Fraud Investigation with the Schall Law Firm - PR Newswire
Piper Sandler lowers Sarepta Therapeutics stock price target on Elevidys concerns - Investing.com
Sarepta Therapeutics stock sinks after FDA tells company to stop shipping its bestselling drug - Yahoo Finance
Investors in Sarepta Therapeutics, Inc. (SRPT): Protect Your RightsContact Levi & Korsinsky Before August 25, 2025 - TradingView
Sarepta Therapeutics: Why Is SRPT Stock Crashing? - Forbes
Shareholders of Sarepta Therapeutics, Inc. Should Contact The Gross Law Firm Before August 25, 2025 to Discuss Your RightsSRPT - Morningstar
Sarepta Faces FDA Hold on Gene Therapy Trials - TipRanks
Sarepta Stands Ground Against HHS Request To Stop Elevidys Shipments - BioSpace
Sarepta slides as FDA places clinical hold on gene therapy clinical trials (SRPT:NASDAQ) - Seeking Alpha
Sarepta Therapeutics stock rating reiterated at Hold by TD Cowen - Investing.com
Sarepta's Shocking Stand: Company Rejects FDA Request To Pull Gene Therapy Elevidys - Yahoo Finance
SRPT DEADLINE REMINDER: Sarepta Therapeutics, Inc. Investors with Losses are Reminded to Contact BFA Law by the Upcoming August 25 Securities Fraud Deadline - Newsfile
Sarepta Therapeutics stock price target slashed to $0 by H.C. Wainwright - Investing.com
TD Cowen Reiterates Hold Rating on Sarepta Therapeutics (SRPT) - StreetInsider
Sarepta extends losses premarket after refusing FDA’s halt request (SRPT:NASDAQ) - Seeking Alpha
BofA Securities Reiterates Neutral Rating on Sarepta Therapeutics (SRPT) - StreetInsider
Sarepta Therapeutics (NASDAQ:SRPT) Cut to “Hold” at Needham & Company LLC - Defense World
Oppenheimer Cuts Sarepta Therapeutics (NASDAQ:SRPT) Price Target to $41.00 - Defense World
Bank of America Cuts Sarepta Therapeutics (NASDAQ:SRPT) Price Target to $20.00 - Defense World
Leerink Partnrs Has Pessimistic Outlook of SRPT Q2 Earnings - Defense World
What drives Sarepta Therapeutics Inc. stock priceExceptional earning trajectories - PrintWeekIndia
Levi & Korsinsky Notifies Sarepta Therapeutics, Inc. (SRPT) Shareholders of Class Action Lawsuit and August 25, 2025 Deadline - ACCESS Newswire
What analysts say about Sarepta Therapeutics Inc. stockFree Stock Selection - Autocar Professional
Bragar Eagel & Squire, P.C. Reminds Investors That Class - GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Hims & Hers and Sarepta and Encourages Investors to Contact the Firm - GlobeNewswire Inc.
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP - GlobeNewswire
SRPT SECURITIES NEWS: Did Sarepta Therapeutics, Inc. - GlobeNewswire
Q1 Earnings Estimate for SRPT Issued By Leerink Partnrs - Defense World
Sarepta Therapeutics Inc. Stock Analysis and ForecastConsistently superior profits - Jammu Links News
Sarepta Therapeutics’ (SRPT) Hold Rating Reiterated at Needham & Company LLC - Defense World
StockWatch: Sarepta Shares Nosedive after LGMD Gene Therapy Patient Dies - Genetic Engineering and Biotechnology News
This Gene Therapy Maker Refuses to Halt Shipments After Patient Deaths - Men's Journal
Sarepta Therapeutics Announces Layoff of 493 Employees, Including 80 in Ohio, Amid FDA Scrutiny and Stock Decline - Hoodline
Finanzdaten der Sarepta Therapeutics Inc-Aktie (SRPT)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):